MedTrace Logo

CART Therapy in Digestive System Tumors

NCT04780529 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-03-03

No results posted yet for this study

Summary

Chimeric Antigen Receptor T Cells (CART) Therapy in GUYC2C postive Digestive system tumors, include colorectal cancer, gastric cancer, liver cancer, pancreatic cancer, adenocarcinoma of esophagus, cancer of the esophagogastric junction.

Ict-gc is an open, single-center study to evaluate the safety and efficacy of CAR-T-targeted therapy in patients with advanced gastrointestinal tumors.

Conditions

  • Malignant Neoplasms of Digestive Organs

Interventions

BIOLOGICAL

gucy2c cart cells

Patients with advanced malignant gastrointestinal tumors were injected with CART cells

Sponsors & Collaborators

  • Anhui Provincial Cancer Hospital

    collaborator OTHER

  • Innovative Cellular Therapeutics Co., Ltd.

    lead OTHER

Principal Investigators

  • Yifu he · Anhui Provincial Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-31
Primary Completion
2022-04-30
Completion
2026-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04780529 on ClinicalTrials.gov